+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Myeloma"

From
From
From
Chronic Myeloid Leukemia (CML) Treatment Market Report 2026 - Product Thumbnail Image

Chronic Myeloid Leukemia (CML) Treatment Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Multiple Myeloma Market Report 2026 - Product Thumbnail Image

Multiple Myeloma Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Leukapheresis Device Market Report 2026 - Product Thumbnail Image

Leukapheresis Device Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
Blood Cancer Diagnostics - Global Strategic Business Report - Product Thumbnail Image

Blood Cancer Diagnostics - Global Strategic Business Report

  • Report
  • June 2026
  • 372 Pages
  • Global
From
Leukapheresis - Global Strategic Business Report - Product Thumbnail Image

Leukapheresis - Global Strategic Business Report

  • Report
  • June 2026
  • 179 Pages
  • Global
From
Multiple Myeloma Market - Forecast from 2026 to 2031 - Product Thumbnail Image

Multiple Myeloma Market - Forecast from 2026 to 2031

  • Report
  • January 2026
  • 150 Pages
  • Global
From
Hematology Diagnostics Market Analysis and Industry Forecast - Product Thumbnail Image

Hematology Diagnostics Market Analysis and Industry Forecast

  • Report
  • April 2026
  • 128 Pages
  • Global
From
From
From
From
From
From
From
Loading Indicator

Myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is a form of hematological malignancy, which is a cancer of the blood or bone marrow. Myeloma is the second most common type of hematological malignancy, after lymphoma. Symptoms of myeloma include bone pain, anemia, frequent infections, and kidney problems. Treatment options include chemotherapy, radiation therapy, stem cell transplant, and targeted therapy. The myeloma market is a subset of the hematology market, which is a large and growing market. The market is driven by the increasing prevalence of hematological malignancies, as well as advances in treatment options. The market is expected to continue to grow in the coming years, as new treatments are developed and more patients are diagnosed. Some companies in the myeloma market include Bristol-Myers Squibb, Celgene, Novartis, and Takeda. Show Less Read more